<DOC>
	<DOCNO>NCT00237120</DOCNO>
	<brief_summary>This study ass safety efficacy imatinib newly enrol previously untreated patient chronic phase CML .</brief_summary>
	<brief_title>Efficacy , Safety Long-term Prognosis Imatinib Patients Newly Diagnosed With Chronic Myelogenous Leukemia ( Chronic Phase )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Diagnosed Chronic Myelogenous Leukemia Chronic Phase Previously untreated Interferonalpha Performance status normal capable limited selfcare Patients pregnant possibly pregnant Significant hepatic disease Chronic Myelogenous Leukemia advance phase Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Imatinib</keyword>
	<keyword>CML</keyword>
</DOC>